News

27/09/2022

Nanoligent, spin-off of the UAB and the IIB Sant Pau, raised €2.8 M and completed Seed round financing

Nanoligent SL, spin-off of the Autonomous University of Barcelona and the Research Institute of the Hospital de Santa Creu i Sant Pau, focuses on developing new drugs for the treatment of more than 20...

22/09/2022

The scientific-technical service platforms of the Sant Pau Research Institute renew their ISO 9001:2015 certification

The Research Institute of the Hospital de la Santa Creu i Sant Pau has obtained the ISO 9001:2015 certification follow-up audit for its Scientific-Technical Service Platforms, initially obtained in 20...

21/09/2022

IIB Sant Pau joins the commemoration of World Alzheimer’s Day

The World Health Organization (WHO) proclaimed September 21 World Alzheimer's Day in 1994 under the auspices of Alzheimer's Disease International (ADI). The Sant Pau Biomedical Research Institute (II...

19/09/2022

The expression of two glutaminergic genes is associated with the accumulation of the TAU protein in Alzheimer’s disease

A study led by Víctor Montal, researcher at the Research Institute of the Hospital de Santa Creu i Sant Pau - IIB Sant Pau and Jorge Sepulcre, of the Massachusetts General Hospital and Harvard Medica...

16/09/2022

Inhibition of miR-148a decreases the progression of arteriosclerosis

Inhibition of miR-148a reduces the progression of atherosclerosis in a "humanized" mouse model. This is the main conclusion reached by a recent investigation led by CIBERDEM by Dr. Noemi Rotllan, rese...